Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Former Nycomed CSO to Head General Medicine Drug Discovery Unit of Takeda
October 24, 2012
- COPD Treatment Market to Expand 2.8 Times by 2020 Compared to 2011: Fuji-Keizai
October 24, 2012
- Antiepileptic Drug Fycompa Approved in the US: Eisai
October 24, 2012
- Astellas Launches Mirabegron in US
October 24, 2012
- Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
- Astellas Receives Recommendation for Approval of Mirabegron in Europe
October 23, 2012
- Neuropathic Pain Treatment Offered Funding from JST’s Support Program: Nippon Chemiphar
October 23, 2012
- Astellas Launches Gonax for Full-Fledged Entry into Cancer Field
October 23, 2012
- Takeda Moves Up to 5th, Pfizer 1st in Patent Assets Ranking
October 22, 2012
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
- 40% of Doctors Collect Drug Information Via Smartphones: CareNet Survey
October 19, 2012
- Novartis Files for Additional Indication of Pediatric Use for Xolair
October 18, 2012
- Ajinomoto Files NDA for AJH801, 6th Fixed-Dose ARB/CCB Combination in Japan
October 18, 2012
- Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
- Asklep to Set Up 3rd East Asian Subsidiary in South Korea
October 17, 2012
- Denosumab Significantly Reduces Vertebral Fractures in Osteoporosis Patients in PIII Study: Daiichi Sankyo
October 17, 2012
- Asahi Glass Offers CMO Services to Biopharmaceutical Industry Using ASPEX Technology: Dr Kumagai
October 17, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…